Meeting
2019 ASCO Annual Meeting
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.
Authors
Jessica Campf
San Antonio Military Medical Center, Fort Sam Houston, TX
Jessica Campf , Guy T. Clifton , Diane F. Hale , Timothy J. Vreeland , Annelies Hickerson , Jarrod P. Holmes , Jennifer Keating Litton , Rashmi Krishna Murthy , Jason Jerome Lukas , Elizabeth A. Mittendorf , George Earl Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02297698
Citation
J Clin Oncol 37, 2019 (suppl; abstr 556)
DOI
10.1200/JCO.2019.37.15_suppl.556
Abstract #
556
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Evaluation of booster injections in maintaining peak immunity in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus GM-CSF alone after adjuvant trastuzumab in women with HER2-positive breast cancer.
First Author: Snehal Patel
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
First Author: Snehal Patel
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace